scholarly journals Proton-dependent glutamine uptake by aphid bacteriocyte amino acid transporter ApGLNT1

2015 ◽  
Vol 1848 (10) ◽  
pp. 2085-2091 ◽  
Author(s):  
Daniel R.G. Price ◽  
Alex C.C. Wilson ◽  
Charles W. Luetje
2002 ◽  
Vol 283 (5) ◽  
pp. F1011-F1019 ◽  
Author(s):  
Anne M. Karinch ◽  
Cheng-Mao Lin ◽  
Christopher L. Wolfgang ◽  
Ming Pan ◽  
Wiley W. Souba

During chronic metabolic acidosis, renal glutamine utilization increases markedly. We studied the expression of the system N1 (SN1) amino acid transporter in the kidney during chronic ammonium chloride acidosis in rats. Acidosis caused a 10-fold increase in whole kidney SN1 mRNA level and a 100-fold increase in the cortex. Acidosis increased Na+-dependent glutamine uptake into basolateral and brush-border membrane vesicles (BLMV and BBMV, respectively) isolated from rat cortex (BLMV, 219 ± 66 control vs. 651 ± 180 pmol · mg−1 · min−1 acidosis; BBMV, 1,112 ± 189 control vs. 1,652 ± 148 pmol · mg−1 · min−1 acidosis, both P < 0.05). Na+-independent uptake was unchanged by acidosis in BLMV and BBMV. The acidosis-induced increase in Na+-dependent glutamine uptake was eliminated by histidine, confirming transport by system N. SN1 protein was detected only in BLMV and BBMV from acidotic rats. After recovery from acidosis, SN1 mRNA and protein and Na+-dependent glutamine uptake activity rapidly returned to control levels. These data provide evidence that regulation of expression of the SN1 amino acid transporter is part of the renal homeostatic response to acid-base imbalance.


Immunity ◽  
2014 ◽  
Vol 40 (5) ◽  
pp. 692-705 ◽  
Author(s):  
Mako Nakaya ◽  
Yichuan Xiao ◽  
Xiaofei Zhou ◽  
Jae-Hoon Chang ◽  
Mikyoung Chang ◽  
...  

2001 ◽  
Vol 120 (5) ◽  
pp. A153-A153
Author(s):  
S MIYAMOTO ◽  
K KATO ◽  
Y ISHII ◽  
S ASAI ◽  
T NAGAISHI ◽  
...  

2018 ◽  
Vol 24 (2) ◽  
pp. 111-120 ◽  
Author(s):  
Sanjay J. Danthi ◽  
Beirong Liang ◽  
Oanh Smicker ◽  
Benjamin Coupland ◽  
Jill Gregory ◽  
...  

SLC6A19 (B0AT1) is a neutral amino acid transporter, the loss of function of which results in Hartnup disease. SLC6A19 is also believed to have an important role in amino acid homeostasis, diabetes, and weight control. A small-molecule inhibitor of human SLC6A19 (hSLC6A19) was identified using two functional cell-based assays: a fluorescence imaging plate reader (FLIPR) membrane potential (FMP) assay and a stable isotope-labeled neutral amino acid uptake assay. A diverse collection of 3440 pharmacologically active compounds from the Microsource Spectrum and Tocriscreen collections were tested at 10 µM in both assays using MDCK cells stably expressing hSLC6A19 and its obligatory subunit, TMEM27. Compounds that inhibited SLC6A19 activity in both assays were further confirmed for activity and selectivity and characterized for potency in functional assays against hSLC6A19 and related transporters. A single compound, cinromide, was found to robustly, selectively, and reproducibly inhibit SLC6A19 in all functional assays. Structurally related analogs of cinromide were tested to demonstrate structure–activity relationship (SAR). The assays described here are suitable for carrying out high-throughput screening campaigns to identify modulators of SLC6A19.


2013 ◽  
Vol 19 (4) ◽  
pp. 649-656 ◽  
Author(s):  
Kyoichi Kaira ◽  
Minoru Toyoda ◽  
Masato Shino ◽  
Koichi Sakakura ◽  
Katsumasa Takahashi ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document